Почетна › Метастатски карцином › Alabama
Kliničke studije za Метастатски карцином u državi Alabama
14 studija za Метастатски карцином traži učesnike na lokacijama u državi Alabama.
Gradovi u državi Alabama
Zvanični tekst studije (na engleskom)
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- Clinical Study Site, Birmingham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07335497Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Alabama at Birmingham Cancer Center, Birmingham
- University of South Alabama Mitchell Cancer Institute, Mobile
Тражи се учесникФаза 2
Сви узрасти · Оба пола · Ажурирано 12. 11. 2026. · NCT05564377Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT04886804LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- Central Alabama Research, Birmingham
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06216301Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Clearview Cancer Institute, Huntsville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT07562152A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07213804A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Clearview Cancer Institute, Huntsville
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06119581Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- The University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT06943755A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT04657068A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- The Kirklin Clinic of UAB Hospital, Birmingham
- The University of Alabama at Birmingham, Birmingham
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT06989437PRE-ISPY Phase I/II Oncology Platform Program
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 30. 9. 2026. · NCT05868226A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Daphne
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 25. 9. 2026. · NCT06103864HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- University of Alabama at Birmingham Cancer Center, Birmingham
Тражи се учесникФаза 1
36 Months – 22 Years · Оба пола · Ажурирано 4. 9. 2026. · NCT03911388SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Birmingham
- Massive Bio SYNERGY-AI site, Mobile
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 28. 10. 2025. · NCT03452774Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.